Design Therapeutics/DSGN

$2.85

-3.71%
-
1D1W1MYTD1YMAX

About Design Therapeutics

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company’s lead product candidate is Friedreich ataxia (FA). Its second product candidate is Fuchs Endothelial Corneal Dystrophy (FECD). It is also advancing its GeneTAC program to address other serious nucleotide repeat-driven monogenic diseases. Its FA is a devastating monogenic, autosomal recessive progressive disease. The FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD. Its Myotonic Dystrophy Type-1 (DM1) is a monogenic, autosomal dominant, progressive neuromuscular disease that affects skeletal muscle, heart, brain, and other organs.

Ticker

DSGN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Pratik Shah

Employees

57

Headquarters

Carlsbad, United States

DSGN Metrics

BasicAdvanced
$161.29M
Market cap
-
P/E ratio
-$1.29
EPS
-
Beta
-
Dividend rate

What the Analysts think about DSGN

Analyst Ratings

Majority rating from 4 analysts.
Hold

Price Targets

Average projection from 4 analysts.
66.67% upside
High $6.00
Low $4.00
$2.85
Current price
$4.75
Average price target

DSGN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-15.7M
-21.11%
Profit margin
0%
-

DSGN Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 31.46%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.31
-$0.35
-$0.36
-$0.28
-
Expected
-$0.34
-$0.36
-$0.40
-$0.41
-$0.31
Surprise
-9.88%
-2.57%
-9.43%
-31.46%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Design Therapeutics stock

Buy or sell Design Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing